COVID vaccine developer BioNTech sees profits rise

  • Lights burn in the main building of the BioNTech manufacturing plant in Marburg, central Germany, Sunday, Nov. 7, 2021.

    Lights burn in the main building of the BioNTech manufacturing plant in Marburg, central Germany, Sunday, Nov. 7, 2021. Associated Press

  • Lights burn around the main building of the BioNTech manufacturing plant, center, in Marburg, central Germany, Sunday, Nov. 7, 2021.

    Lights burn around the main building of the BioNTech manufacturing plant, center, in Marburg, central Germany, Sunday, Nov. 7, 2021. Associated Press

 
 
Updated 11/9/2021 8:18 AM

BERLIN -- German pharmaceutical company BioNTech, which partnered with Pfizer to develop the first widely used COVID-19 vaccine, said Tuesday that its earnings grew again in the third quarter.

BioNTech, which is based in Mainz, reported a net profit of more than 3.2 billion euros ($3.7 billion) for the July-September period. That compares with the company's loss of 210 million euros ($243 million) in the same period a year earlier and a second-quarter profit of almost 2.8 billion euros ($3.2 billion). Vaccinations with the Pfizer-BioNTech vaccine started started in December.

 

BioNTech reported revenue of nearly 6.1 billion euros ($7.1 billion), up from 67.5 million euros ($78 million) in the third quarter of 2020. It said that more than 2 billion doses of the COVID-19 vaccine, marketed as Comirnaty, had been delivered this year as of Nov. 2.

Based on an expected total of up to 2.5 billion doses, BioNTech said it predicts revenue from the coronavirus vaccine for the full year to add up to 16 to 17 billion euros ($18.5 billion to $19.7 billion).

The company has said the windfall from its mRNA-based coronavirus vaccine will help it to develop drugs against cancer and other diseases.

BioNTech's net profit for the year's first nine months was over 7.1 billion euros ($8.2 billion), compared with a loss of 351.7 million euros ($407 million) in the same period a year earlier.

___

Follow AP's pandemic coverage at https://apnews.com/hub/coronavirus-pandemic

0 Comments
                                                                                                                                                                                                                       
 
Article Comments
Guidelines: Keep it civil and on topic; no profanity, vulgarity, slurs or personal attacks. People who harass others or joke about tragedies will be blocked. If a comment violates these standards or our terms of service, click the X in the upper right corner of the comment box. To find our more, read our FAQ.